The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma

British Journal of Cancer

Volumn 111, Issue 3, 2014, Pages 628-636

  Wu, W ^a,b   Merriman, K ^a   Nabaah, A ^a   Seval, N ^a   Seval, D ^a   Lin, H ^a   Wang, M ^a   Qazilbash, M H ^a   Baladandayuthapani, V ^a   Berry, D ^a   Orlowski, R Z ^a   Lee, M H ^a   Yeung, S C J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; THALIDOMIDE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 14; CHROMOSOME TRANSLOCATION; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG CONTRAINDICATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; STEROID INDUCED DIABETES; SURVIVAL PREDICTION;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905226036     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.307     Document Type: Article

References (34)

1. Benetatos L, Vartholomatos G (2012) Deregulated microRNAs in multiple myeloma. Cancer 118(4): 878-887.
2. Boffetta P, Stellman SD, Garfinkel L (1989) A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer 43(4): 554-559.
3. Bommert K, Bargou RC, Stuhmer T (2006) Signalling and survival pathways in multiple myeloma. Eur J Cancer 42(11): 1574-1580.
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373-383.
5. Chou YS, Yang CF, Chen HS, Yang SH, Yu YB, Hong YC, Liu CY, Gau JP, Liu JH, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT (2012) Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol 89(4): 320-327.
6. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159(12): 1160-1167.
7. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, Rothman N, Bernstein L, Hartge P, Morhbacher A, Coetzee SG, Salam MT, Wang W, Zadnick J, Ingles SA (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15(11): 2285-2291.
8. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International Myeloma Working G (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9): 1467-1473.
9. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15(4): 825-836.
10. Fortuny J, Benavente Y, Bosch R, Garcia-Villanueva M, de Sevilla AF, de Sanjose S (2005) Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer 41(12): 1782-1787.
11. Freund GG, Kulas DT, Mooney RA (1993) Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151(4): 1811-1820.
12. Freund GG, Kulas DT, Way BA, Mooney RA (1994) Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54(12): 3179-3185.
13. Gado K, Silva S, Paloczi K, Domjan G, Falus A (2001) Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica 86(3): 227-236.
14. Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31(23): 2963-2969.
15. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. CACancer J Clin 60(4): 207-221.
16. He XX, Tu SM, Lee MH, Yeung SC (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22(12): 2640-2645.
17. Hofmann JN, Moore SC, Lim U, Park Y, Baris D, Hollenbeck AR, Matthews CE, Gibson TM, Hartge P, Purdue MP (2013) Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol 177(8): 776-786.
18. Huang Q, Shi J, Feng A, Fan X, Zhang L, Mashimo H, Cohen D, Lauwers G (2011) Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol 24(1): 138-146.
19. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ (2012) Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16): 3260-3270.
20. Mahindra A, Cirstea D, Raje N (2010) Novel therapeutic targets for multiple myeloma. Future Oncol 6(3): 407-418.
21. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K (2009) The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 115(2): 49-57.
22. Nilsen TI, Vatten LJ (2001) Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 84(3): 417-422.
23. Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, Konopleva M, Andreeff M, Lee MH, Yeung SC (2012) Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle 11(12): 2314-2326.
24. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, Waage A, Iversen PO (2009) Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 83(5): 460-470.
25. Richardson LC, Pollack LA (2005) Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2(1): 48-53.
26. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10): 2905-2912.
27. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, Goldschmidt H, Klein B (2010) Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 24(11): 1940-1950.
28. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4): 492-499.
29. Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26(4): 1047-1051.
30. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC (2012) A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma, Myeloma & Leukemia 12(5): 355-362.
31. Wallin A, Larsson SC (2011) Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 47(11): 1606-1615.
32. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM (2004) Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100(6): 1179-1185.
33. Wentholt IM, Hart AA, Hoekstra JB, DeVries JH (2008) Evaluating clinical accuracy of continuous glucose monitoring devices: other methods. Curr Diabetes Rev 4(3): 200-206.
34. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A (1997) Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 97(2): 429-440.